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Purpose/Objective: Of all the possible radiotherapy modalities for 
localized prostate cancer, none offers such operator dependency as 
brachytherapy (BT). There are significant traps and risks that need to 
be mastered before a BT 'team' is skilled enough to perform the 
procedure. This competence occurs only after a BT 'team' has 
performed a certain number of procedures. In this work, the learning 
curve of our BT 'team' performing prostate high dose rate (HDR) BT 
with transrectal ultrasound (TRUS) guided real-time treatment 
planning was studied. To this aim, a new index called Optimal 
PlanIndex (OPI) was proposed. Moreover, dosimetric data about the 
first 60 treatments performed with this technique were analysed. 
Materials and Methods: In December 2009 a new HDR BT facility was 
implemented for prostate treatments at INT. Since this date, 60 
patients were selected according to GEC/ESTRO-EAU 
recommendations for temporary HDR prostate BT using an Ir-192 
stepping source. TRUS-guided real-time treatment planning was 
adopted as the standard procedure instead of CT imaging. The major 
steps of this procedure are: i) a first ultrasound scan to perform 
treatment pre-planning. In this phase, needles location is decided; ii) 
patient implant; needles location might change from the one 
previously decided on the virtual pre-plan; iii) a second ultrasound 
scan is finally performed to guide the definitive treatment planning. 
All HDR treatments were then performed using a MicroSelectron-
HDR(Nucletron) facility. The delivered dose per fraction was of 14Gy. 
All needles were immediately removed after treatment. To evaluate 
the learning curve of our BT 'team' to performing this procedure, a 
new index called Optimal Plan Index (OPI) was defined as the dose to 
95% of the prostate divided by the dose to 0.1cc of the urethra.  
Results: To evaluate the learning curve of the BT 'team', Dose 
Homogeneity Index (DHI), Conformity Index (COIN) as well as OPI were 
analysed. DHI and COIN didn’t show any correlation with the BT 'team' 
increasing experience, whereas OPI resulted to be a good indicator of 
the learning curve. The lowest value of OPI was obtained on 
treatment number 12, where the pubic arc obstruction was 
erroneously estimated. The number of adopted needles with respect 
to the prostate volume was as well investigated to verify and possibly 
modify treatment planning strategies. 
Conclusions: In contrary to the already existing DHI and COIN, the 
newly proposed OPI was a good indicator of the learning curve of our 
BT 'team' Analysis of the stored dosimetric data was useful to 
investigate and possibly modify treatment planning strategies (e.g., 
number of needles with respect to the prostate volume, optimization 
algorithm). 
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Purpose/Objective: We describe five patients receiving a re-
implantation (RI) after post-operative dosimetry of the primary 125-I 
permanent brachytherapy (BT) for prostate cancer revealed an 
insufficient dose coverage. 
Materials and Methods: Out of 222 consecutive patients treated (from 
March, 2001 to August, 2012) with 125-I BT, dosimetric verification by 
CT and MRI fusion four to eight weeks after implantation displayed an 
insufficient dose coverage in five patients. In these patients, a RI with 
10 to 19 seeds was performed three to four months after primary 
intervention. Dosimetry after RI showed an improved and sufficient 
total dose coverage in all patients. 
Results: At last follow-up (18 to 99 months, median 57 months), none 
of the patients had relevant implant associated side-effects. 
Functional outcome was comparable to patients after one-time 
implantation. PSA levels post intervention showed a decreasing 
tendency in 4 patients. One patient had a local recurrence after 12 
months. The D5% (Dose to 5% of the urethra volume) was aimed to be 
below 150% (217.5Gy) of the prescribed dose for primary 
implantation. During salvage re-implantation these criteria were not 
met in any of the 5 cases. The D5 values ranged from 221Gy to 376Gy. 
The volume of the rectum receiving 100% of the prescribed dose was 
aimed to stay under 0.3cm3 (VR100%), this was exceeded in five re-
implantations; the volumes ranged from 0.4cm3 to 5 cm3. Despite 
exceeding typical urethral and rectal dose constraints, toxicities were 
not observed. 
Conclusions: In our series, approximately 2% of the patients treated 
with permanent prostate BT required and received a RI due to 
insufficient dose coverage. None of the patients who underwent RI 
experienced complications. Our series, along with other published 
reports, demonstrates good tolerability.  
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Purpose/Objective: High dose rate brachytherapy (HDRBT) has been 
established as an effective technique for dose escalation boost 
delivered in combination with external beam radiotherapy (EBRT). 
The placement of the needles is usually guided by transrectal 
ultrasound (TRUS). Modern ultrasound equipment and dedicated 
software enable real-time ultrasound based treatment planning. Such 
procedure has been used at Oslo University Hospital since 2007.  
Materials and Methods: We have analysed 192 patients treated with 
HDRBT from January 2009 until October 2012 using Oncentra Prostate 
software. The HDRBT was delivered about four weeks prior to the 
EBRT using two fractions separated by two weeks. The CTV was 
defined as the prostate gland plus a 2 mm margin to account for 
possible extracapsular disease. The planning aim was to deliver 10 Gy 
to the CTV per fraction with a dose constraint of 12 Gy and 6.6 Gy to 
the urethra D0.1cc and the rectum D2cc, respectively. 
Results: The prostate gland and the CTV had an average volume of 
26.1 ± 8.7cc and 35.5 ± 10.7cc, respectively, and were treated using 
an average of 16 ± 2 needles. The D90 of the CTV was on average 10.5 
± 0.3 Gy, with 95% of the treatments resulting in a D90 of 10.0 Gy or 
higher. In average the urethra D0.1cc and the rectum D2cc was 11.4 ± 
0.5Gy and 5.7 ± 0.7 Gy, respectively. For the whole treatment cohort 
an average conformity index (COIN) of 0.84 ± .04 was found. In 
average there was not found any significant change in the delineated 
prostate gland volume between the first and the second 
brachytherapy fraction, even for the group of patients where the 
same doctor performed delineation for both fractions thus eliminating 
interobserver variations. As expected, a positive correlation (R2 of 
0.42) was found between the prostate volume and the number of 
needles used. CTV volume and D90 was found to be uncorrelated. 
However, the analysis also showed a weak positive correlation 
between CTV volume and COIN, indicating that we were able to 
achieve higher conformity for larger prostate volumes.  
Conclusions: Using real-time TRUS based HDRBT technique we were 
able to achieve a D90 at our planning aim for more than 95% of our 
patients without violating the OAR constraints. 
 
   
